The startup develops a medical device platform that automates the on-site production and infusion of water in PET scanner suites, enhancing blood flow imaging for diagnostic applications. This technology enables precise quantification of blood flow, facilitating improved assessments in cardiac, brain, and tumor vascularization studies.
Funding
$71.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for quantifying blood flow using PET imaging often rely on manual processes and lack the precision needed for accurate diagnosis and monitoring. The limited availability and complex logistics of producing and administering the 15O-water tracer also restrict wider clinical adoption.
Solution
MedTrace is developing an automated, on-site solution for the production, delivery, and quantification of 15O-water, a gold-standard PET tracer for assessing absolute blood flow. Their system integrates a bedside chemistry module with analytical software to streamline the perfusion imaging workflow. The aQuant software package provides clinicians with tools to quantify myocardial blood flow and perfusion based on 15O-water PET data. By automating the 15O-water process, MedTrace aims to improve the accuracy and accessibility of perfusion imaging for various clinical applications.
Target Audience
The primary target audience includes hospitals, imaging centers, and clinical research facilities utilizing PET scanners for cardiac, neurological, and oncological applications.
Features
- Automated chemistry system for on-site manufacturing and infusion of 15O-water
- aQuant software for quantifying myocardial blood flow and perfusion
- Streamlined workflow for 15O-water PET imaging
- Intended for use with an on-site cyclotron